High-dose, short-interval daptomycin regimen was safe and well tolerated in three patients with chronic renal failure

Kaori Yabuno,1,2,* Masafumi Seki,1,* Koji Miyawaki,1,2 Yoshihiro Miwa,2 Kazunori Tomono11Division of Infection Control and Prevention, 2Department of Pharmacy, Osaka University Hospital, Osaka, Japan *These authors contributed equally to this workBackground: The recommended daptomycin dosage is 4 or...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yabuno K, Seki M, Miyawaki K, Miwa Y, Tomono K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/49ba6b499cff4757953b605f740594cc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:49ba6b499cff4757953b605f740594cc
record_format	dspace
spelling	oai:doaj.org-article:49ba6b499cff4757953b605f740594cc2021-12-02T03:25:04ZHigh-dose, short-interval daptomycin regimen was safe and well tolerated in three patients with chronic renal failure1179-1438https://doaj.org/article/49ba6b499cff4757953b605f740594cc2013-11-01T00:00:00Zhttp://www.dovepress.com/high-dose-short-interval-daptomycin-regimen-was-safe-and-well-tolerate-a14888https://doaj.org/toc/1179-1438Kaori Yabuno,1,2,* Masafumi Seki,1,* Koji Miyawaki,1,2 Yoshihiro Miwa,2 Kazunori Tomono11Division of Infection Control and Prevention, 2Department of Pharmacy, Osaka University Hospital, Osaka, Japan *These authors contributed equally to this workBackground: The recommended daptomycin dosage is 4 or 6 mg/kg/day for the treatment of complicated skin and soft tissue infections or for Staphylococcus aureus bacteremia, endocarditis, and osteomyelitis. Every other day administration is usually recommended for patients with mild to moderate renal impairment. Higher doses (>6 mg/kg/day) have been explored as a possible alternative. Daptomycin is considered a safe anti-methicillin-resistant S. aureus (MRSA) drug, although renal dysfunction may be worsened. In this paper we report on three patients with chronic renal failure who received a higher dose of daptomycin daily for successful treatment for MRSA bacteremia, MRSA osteomyelitis, and methicillin-resistant S. epidermidis (MRSE) endocarditis.Results: Previous administration of other drugs, including vancomycin, teicoplanin, and linezolid, had failed. In spite of daily treatment with daptomycin instead of the recommended alternate day regimen, adverse effects, such as elevation of creatinine and creatine phosphokinase, did not occur.Conclusion: These experiences suggest that administration of high-dose/short-interval daptomycin can be efficient and safe even in the setting of renal dysfunction, and should be considered for the treatment of severe MRSA/MRSE infections in these patients.Keywords: daptomycin, high-dose, renal failure, methicillin-resistant Staphylococcus aureus, creatine phosphokinaseYabuno KSeki MMiyawaki KMiwa YTomono KDove Medical PressarticleTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol 2013, Iss Issue 1, Pp 161-166 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Therapeutics. Pharmacology RM1-950
spellingShingle	Therapeutics. Pharmacology RM1-950 Yabuno K Seki M Miyawaki K Miwa Y Tomono K High-dose, short-interval daptomycin regimen was safe and well tolerated in three patients with chronic renal failure
description	Kaori Yabuno,1,2,* Masafumi Seki,1,* Koji Miyawaki,1,2 Yoshihiro Miwa,2 Kazunori Tomono11Division of Infection Control and Prevention, 2Department of Pharmacy, Osaka University Hospital, Osaka, Japan *These authors contributed equally to this workBackground: The recommended daptomycin dosage is 4 or 6 mg/kg/day for the treatment of complicated skin and soft tissue infections or for Staphylococcus aureus bacteremia, endocarditis, and osteomyelitis. Every other day administration is usually recommended for patients with mild to moderate renal impairment. Higher doses (>6 mg/kg/day) have been explored as a possible alternative. Daptomycin is considered a safe anti-methicillin-resistant S. aureus (MRSA) drug, although renal dysfunction may be worsened. In this paper we report on three patients with chronic renal failure who received a higher dose of daptomycin daily for successful treatment for MRSA bacteremia, MRSA osteomyelitis, and methicillin-resistant S. epidermidis (MRSE) endocarditis.Results: Previous administration of other drugs, including vancomycin, teicoplanin, and linezolid, had failed. In spite of daily treatment with daptomycin instead of the recommended alternate day regimen, adverse effects, such as elevation of creatinine and creatine phosphokinase, did not occur.Conclusion: These experiences suggest that administration of high-dose/short-interval daptomycin can be efficient and safe even in the setting of renal dysfunction, and should be considered for the treatment of severe MRSA/MRSE infections in these patients.Keywords: daptomycin, high-dose, renal failure, methicillin-resistant Staphylococcus aureus, creatine phosphokinase
format	article
author	Yabuno K Seki M Miyawaki K Miwa Y Tomono K
author_facet	Yabuno K Seki M Miyawaki K Miwa Y Tomono K
author_sort	Yabuno K
title	High-dose, short-interval daptomycin regimen was safe and well tolerated in three patients with chronic renal failure
title_short	High-dose, short-interval daptomycin regimen was safe and well tolerated in three patients with chronic renal failure
title_full	High-dose, short-interval daptomycin regimen was safe and well tolerated in three patients with chronic renal failure
title_fullStr	High-dose, short-interval daptomycin regimen was safe and well tolerated in three patients with chronic renal failure
title_full_unstemmed	High-dose, short-interval daptomycin regimen was safe and well tolerated in three patients with chronic renal failure
title_sort	high-dose, short-interval daptomycin regimen was safe and well tolerated in three patients with chronic renal failure
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/49ba6b499cff4757953b605f740594cc
work_keys_str_mv	AT yabunok highdoseshortintervaldaptomycinregimenwassafeandwelltoleratedinthreepatientswithchronicrenalfailure AT sekim highdoseshortintervaldaptomycinregimenwassafeandwelltoleratedinthreepatientswithchronicrenalfailure AT miyawakik highdoseshortintervaldaptomycinregimenwassafeandwelltoleratedinthreepatientswithchronicrenalfailure AT miway highdoseshortintervaldaptomycinregimenwassafeandwelltoleratedinthreepatientswithchronicrenalfailure AT tomonok highdoseshortintervaldaptomycinregimenwassafeandwelltoleratedinthreepatientswithchronicrenalfailure
_version_	1718401791589089280

High-dose, short-interval daptomycin regimen was safe and well tolerated in three patients with chronic renal failure

Ejemplares similares